HER2-targeted antibody-drug conjugate linking trastuzumab to the microtubule inhibitor DM1; after HER2 binding and internalization, DM1 disrupts microtubules while trastuzumab retains HER2 blockade and ADCC.
HER2-targeted antibody–drug conjugate linking trastuzumab to the microtubule inhibitor DM1 via a nonreducible linker. After HER2 binding and internalization, intracellular DM1 disrupts microtubule dynamics to inhibit cell division and induce apoptosis, while the trastuzumab component blocks HER2 signaling and mediates Fc-dependent ADCC.
NO
INDIRECT
T-DM1 binds HER2 and is internalized; the DM1 payload then binds beta-tubulin to disrupt microtubules, causing mitotic arrest and apoptosis. Beta-tubulin expression alone does not make cells targets for killing.
An anti-CD38 IgG1 monoclonal antibody that mediates ADCC, CDC, ADCP, direct apoptosis, and immune modulation, including depletion of CD38+ immunosuppressive cells.
Human IgG1k monoclonal antibody targeting CD38; binding to CD38 on malignant plasma cells triggers immune effector–mediated killing (ADCC, ADCP, CDC) and direct apoptosis, and depletes CD38+ immunosuppressive cells (Tregs, Bregs, MDSCs), enhancing anti-tumor immunity.
YES
DIRECT
Daratumumab binds CD38 on target cells and triggers NK cell ADCC, macrophage ADCP, and complement-dependent cytotoxicity; Fc crosslinking can also induce direct apoptosis of CD38+ cells.
Monoclonal antibody targeting Claudin 18.2 on tumor cells, promoting ADCC and CDC against CLDN18.2-expressing gastric/GEJ cancer cells.
ASKB589 is an unconjugated monoclonal antibody against Claudin 18.2. By binding CLDN18.2 on tumor cells, it triggers Fc-mediated immune effector functions—antibody-dependent cellular cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC)—resulting in selective killing of CLDN18.2-positive gastric/GEJ cancer cells.
YES
DIRECT
Binds CLDN18.2 on target cells and engages immune effectors via Fc to induce ADCC and complement activation (CDC), causing lysis of CLDN18.2-positive cells.
Fc-glycosylated, fully humanized anti-CTLA-4 monoclonal antibody immune checkpoint inhibitor that blocks CTLA-4 to enhance CD28-mediated T-cell priming and may deplete Tregs via ADCC/CDC.
Fully humanized anti-CTLA-4 monoclonal antibody that blocks CTLA-4 interactions to enhance CD28-mediated T-cell priming; Fc glycosylation maintains effector function enabling depletion of intratumoral regulatory T cells via ADCC/CDC.
YES
DIRECT
Antibody binds CTLA-4 on Tregs and, via its Fc, recruits immune effectors to deplete them through ADCC/ADCP and complement-dependent cytotoxicity (CDC).
Investigational antibody–drug conjugate (ADC) designed to deliver a cytotoxic payload to tumor antigen–expressing cells.
Human IgG1 anti-HER3 antibody linked via a cleavable peptide linker to a DNA topoisomerase I inhibitor. After binding HER3 on tumor cells, the ADC is internalized and the payload is released to inhibit topoisomerase I, causing DNA breaks, blocking DNA replication, and inducing apoptosis in HER3-expressing cells.
YES
DIRECT
ADC binds HER3 on tumor cells, is internalized, and releases a topoisomerase I inhibitor that induces DNA breaks, blocks replication, and triggers apoptosis in HER3-expressing cells.